Compare Halliburton Company (HAL) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Revvity Inc — how do they compare? Halliburton Company trades at $32.44 (market cap $26.45B), while Revvity Inc trades at $152.05 (market cap $17.14B). The key difference: Halliburton Company is the larger of the two by market cap, and Halliburton Company pays the higher dividend (2.14%). Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and Revvity Inc for 12 Days on average.
| HAL | RVTY | |
|---|---|---|
Market Cap | $26.45B | $17.14B |
Volume | 11,229,274 | 2,226,396 |
Sector | Energy | Health |
52-Week High | $42.98 | $157.36 |
52-Week Low | $21.82 | $82.26 |
Typical Hold Time | 89 Days | 12 Days |
Enterprise Value | $32.60B | $19.46B |
Dividend Yield | 2.14% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $32.57, down 0.46% on the day, amid a bearish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent news highlights expansion in Venezuela and a major contract win in Cyprus, signaling growth initiatives. Financials show solid profitability with a net income margin of 7.16% and a P/E ratio of 16.62, though 2025 revenue dipped slightly to $22.18 billion.
The outlook is supported by strong analyst consensus with a $43.11 price target and 73% buy ratings, but risks include oil price volatility and execution challenges in new markets. Cash flow trends have been mixed, with 2025 net cash flow negative $412 million, though 2026 projects a return to positive territory.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28. The stock shows bullish technical momentum with consistent earnings beats in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. Operating cash flow improved to $628 million in 2026 from $583 million in 2025.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics pose near-term risks. The company faces margin pressures in China and competitive challenges. With 52% analyst buy ratings and strong institutional interest, the stock offers upside to the $165 high target but requires monitoring of Q3 earnings due November 3.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
